HTG2014-Section-Header-publications

Categories

Filter by Topics

ALK Apoptosis Asthma Autocrine Signaling B Cells benign Biofluid Biomarker Analysis Biomarker Discovery Biomarker Validation Biomarkers Bladder Cancer Breast Cancer Breast milk Cancer Genomics Cells Cerebrospinal Fluid Childhood Atopic Dermatitis Chronic Obstructive Pulmonary Disease Circulating miRNAs Colorectal cancer Comparative Study Comparison study computational toxicology Core Needle Biopsy COVID-19 Custom mRNA Cytokines Cytotoxic T Cells Dementia Diabetes Differential Expression Differential Gene Expression Analysis DLBCL Drug Response Drug Safety Drug Targets Drug-induced Liver Injury EGFR Muatations EMT epidemiology epigenomics Epstein-Barr Esophageal Cancer Exosomes Extracellular Vesicles Fabry Disease Feasibility FFPE FGF Ligand Trap Fibrous Tumors Gene Expression Profiling Gene Signature Analysis Glioblastoma Tumors Head and Neck Cancer Heart HTG EdgeSeq ALKPlus Assay EU HTG EdgeSeq Custom Assays HTG EdgeSeq DLBCL Cell of Origin Assay HTG EdgeSeq DLBCL-COO-CE-IVD HTG EdgeSeq Immune Response Panel HTG EdgeSeq Immuno-Oncology Assay HTG EdgeSeq miRNA Whole Transcriptome Assay HTG EdgeSeq miRNA Whole Transcriptome Panel HTG EdgeSeq Mouse mRNA Tumor Response Panel HTG EdgeSeq Oncology Biomarker Panel HTG EdgeSeq Path Assay HTG EdgeSeq Precision Immuno-Oncology Panel HTG EdgeSeq Precision Immunol-Oncology Panel HTG EdgeSeq System HTG EdgeSeq System Oncology Biomarker Panel HTG EdgSeq Immuno-Oncology Assay ibrutinib Immune Checkpoint Inhibitors Immune Related Genes Immune Response Immune Tolerance Immuno-Oncology immunohistochemistry IHC Immunotherapy Inflammation Juvenile Arthritis Kidney Liquid Biopsy Liver Lung Lung cancer Lymph Node Metastasis Lymphoma machine learning malignant Mechanism of Action Melanoma Mesothelioma Microenvironment MicroRNA miRNA Molecular Characterization Mouse mRNA custom mTOR pathway multi-omics Muscle Mutations NAFLD Nash and Fibrosis Neoantigens Neuroendocrine Tumor Neurologic Oncology Oral Cancer Osteoclast Ovarian cancer Pancreas Paralysis Pathogenesis Pathway analysis Pathway Analysis PCA Cell Lines PD-1 PD-L1 placenta Placenta Plasma predictive biology Predictive Biomarkers Predictive Modeling Progression free-survival Prostate Prostate Cancer qNPA Reproductive Response rate Reveal Rheumatoid Arthritis Risk Score Sarcoma Serum Signaling Inhibitors Signatures Sinonasal Carcinoma Skin SPECS Lung Consortium Squamous cell carcinoma Sub-typing surface plasmon Surveillance Survival Outcomes Synovial Fluid synthetic miRNA T-Cell T-cells Technology Comparison Therapeutic targets Thyroid Cancer TMB Toxicity Translational Medicine Treatment Outcome Tumor Biology Tumor Heterogeneity Tumor Microenvironment Urothelial carcinoma Uterus Wound healing Xenograft Tissue

2021

High-dimensional and single-cell transcriptome analysis of tumor microenvironment in angioimmunoblastic T cell lymphoma AITL)

Pritchett, J. C., et al., High-dimensional and single-cell transcriptome analysis of tumor microenvironment in angioimmunoblastic T cell lymphoma AITL), Leukemia 2021. https://doi.org/10.1038/s41375-021-01321-2

View External Link

2020

Immunomodulatory drugs may overcome the negative prognostic role of active Th17 axis in follicular lymphoma: evidence from the SAKK35/10 trial

Menter, T., et al. Immunomodulatory drugs may overcome the negative prognostic role of active Th17 axis in follicular lymphoma: evidence from the SAKK35/10 trial.  British Journal of Haematology; 2020 Jun. doi: 10.1111/bjh.16876

Download pdf 858KB

Prognostic Factors, Therapeutic Approaches, and Distinct Immunobiologic Features in Patients with Primary Mediastinal Large B-cell Lymphoma on Long-term Follow-up

Zhou H., et al. Prognostic Factors, Therapeutic Approaches, and Distinct Immunobiologic Features in Patients with Primary Mediastinal Large B-cell Lymphoma on Long-term Follow-up. Blood Cancer Journal (2020)10:49

Download pdf 1.0MB

2019

Molecular Characteristics of Diffuse Large B-Cell Lymphoma and Correlation with baseline Metabolic Tumor volume (MTV), Interim Positron Emission Tomography (iPET) and Outcome in the PETAL Trial.

Richter, J., et al. Molecular Characteristics of Diffuse Large B-Cell Lymphoma and Correlation with Baseline Metabolic Tumor Volume (MTV), Interim Positron Emission Tomography (iPET) and Outcome in the PETAL Trial. Blood Cancer Journal 2019 Aug 19; 9(67).

Download pdf 757KB

The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models

Hicks, S. W., et al. The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models. Hematologica. 2019 Feb 7; 104(8):1633-1639

Download pdf 1.5MB

Nivolumab for Relapsed/Refractory Diffuse Large B-cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study

Ansell, S. M., et al. Nivolumab for Relapsed/Refractory Diffuse Large B-cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study. Journal of Clinical Oncology. 2019 Jan 8:37(6):481-489

Download pdf 873KB

2018

Comparison of Immunohistochemistry Assay Results with Gene Expression Profiling Methods for Diffuse Large B-Cell Lymphoma Subtype Identification in Matched Patient Samples.

Schaffer, M., et al. Comparison of Immunohistochemistry Assay Results with Gene Expression Profiling Methods for Diffuse Large B-Cell Lymphoma Subtype Identification in Matched Patient Samples. J Mol Biomark Diagn 2018, 9:2 DOI: 10.4172/2155-9929.1000386

Download pdf 1.3MB

PQR309 is a novel dual P13K/mTOR inhibitor with pre-clinical anti-tumor activity in lymphomas as a single agent and in combination therapy.

Bertoni, F., et al. PQ309 is a novel dual P13K/mTOR inhibitor with pre-clinical anti-tumor activity in lymphomas as a single agent and in combination therapy. Clin Cancer Res. Clin Cancer Res. 2018 Jan 1;24(1):120-129. doi: 10.1158/1078-0432.CCR-17-1041. Epub 2017 Oct 24. [Epub ahead of print].

PMID: 29066507

View External Link

2017

Page last updated September 16, 2021